Business News • PR NewsWire • Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI), at the ARVO 2017 Annual Meeting

Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI), at the ARVO 2017 Annual Meeting

Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI), at the ARVO 2017 Annual Meeting

PARIS, May 12, 2017 /PRNewswire/ -- Pharmacology research conducted in conjunction with The Vision Institute, Paris Pharmaleads, an emerging pharmaceutical company developing innovative products for the management of acute and chronic severe pain, today announced positive effica...

View More : http://www.prnewswire.com/news-releases/pharmaleads-reports-positive-ocular-pain-results-with-pl265-a-novel-dual-enkepha...

Releted News by prnewswire

Ecopetrol Business Group presents First Quarter 2017 Results

ASU + GSV Summit: Invited for Second Consecutive Year! Liulishuo Challenges "The Three Deadly Sins of Education" through AI